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SapropterinPhenylketonuria (PKU) is a rare genetic condition characterized by an absence or mutation of the PAH
enzyme, which is necessary for the metabolism of the amino acid phenylalanine into tyrosine. Recently,
sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4), has been introduced as a
supplemental treatment to dietary phe control for PKU. Very little is known regarding BH4 treatment and
its effect on brain and cognition. The present study represents the ﬁrst examination of potential changes
in neural activation in patients with PKU during BH4 treatment. To this end, we utilized an n-back working
memory task in conjunction with functional magnetic resonance imaging (fMRI) to evaluate functional
brain integrity in a sample of individuals with PKU at three timepoints: Just prior to BH4 treatment, after
4 weeks of treatment, and after 6 months of treatment. Neural activation patterns observed for the PKU
treatment group were compared with those of a demographically-matched sample of healthy non-PKU
individuals who were assessed at identical time intervals. Consistent with past research, baseline evaluation
revealed impaired working memory and atypical brain activation in the PKU group as compared to the
non-PKU group. Most importantly, BH4 treatment was associated with improvements in both working
memory and brain activation, with neural changes evident earlier (4-week timepoint) than changes in
working memory performance (6-month timepoint).
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Phenylketonuria (PKU) is an inborn error of metabolism charac-
terized by a disruption in the ability to metabolize the amino acid
phenylalanine (phe) into tyrosine, a precursor for dopamine and
other catecholamines. Individuals with PKU have reduced activity
of the phenylalanine hydroxylase (PAH) enzyme, which is necessary
for this metabolic process to occur. Immediate consequences include
decreased tyrosine levels and increased serum levels of phe (Jervis,
1953). The excess phe further competes with the available tyrosine
and other large neutral amino acids (LNAAs) to cross the blood–brain
barrier. The accumulative consequences of PKU include decreased neu-
rotransmitter production and protein synthesis (Güttler and Lou, 1986;
Hughes and Johnson, 1978; Ribas et al., 2011).al Sciences, 210 McAlester Hall,
s. Tel.: +1 573 884 8140.
.Open access under CC BY-NC-ND liceIndividuals with PKU are typically identiﬁed at birth via newborn
screening, and dietary intervention aimed at limiting phe intake is
begun immediately. Earlier and stricter implementation of treat-
ment is associated with more positive outcome (Koch et al., 2002);
however, individuals with early-treated PKU continue to experience
neurologic and cognitive impairment (Waisbren et al., 2007; Welsh
et al., 1990).
Early-treated PKU is associated with a slight decrease in overall IQ
coupled with more signiﬁcant impairment in particular aspects of cog-
nition, most notably executive function (for review, see Christ et al.,
2010a). Executive function refers to higher-order cognitive abilities
that facilitate the ﬂexible modiﬁcation of thought and behavior in
response to changing cognitive or environmental demands. Executive
function encompasses abilities such as planning, organization, cognitive
ﬂexibility, inhibitory control, and working memory. These abilities are
considered executive because they require the integration and process-
ing of information across a range of cognitive domains, sensory modal-
ities, and response modalities.
From a neurological standpoint, white matter abnormalities rep-
resent the most evident and widely-reported neurologic ﬁnding in
individuals with PKU (Anderson and Leuzzi, 2010). The extent and
severity of such abnormalities appear to be moderated by patient
age and dietary adherence (as reﬂected by blood phe levels), withnse. 
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matter involvement (Antenor-Dorsey et al., 2013; Cleary et al.,
1994; Thompson et al., 1993).
Research in our laboratory has begun to also evaluate the functional
integrity of the brain and its relationship to the aforementioned execu-
tive function impairment associated with PKU. In a recent study (Christ
et al., 2010b), we utilized functional magnetic resonance imaging
(fMRI) to examine neural activation in a sample of individuals with
and without PKU during performance of an n-back working memory
task. Group-related differences in neural activity were found in several
regions (e.g., bilateral dorsolateral prefrontal cortex, anterior cingulate
cortex) known to be important for working memory and executive
function (for review, see Owen et al., 2005).
1.1. Tetrahydrobiopterin (BH4) treatment in PKU
Recently, sapropterin dihydrochloride, a synthetic form of tetra-
hydrobiopterin (BH4), has been introduced as a supplemental treat-
ment to dietary phe control for PKU. BH4 is a naturally-occurring
compound that serves as a cofactor for PAH and other enzymes. Kure
et al. (1999) and a number of subsequent studies have found that BH4
supplementation is effective in lowering blood serum phe levels in a
subset of individuals with PKU (for review, see Hegge et al., 2009).
Although the mechanism of action underlying this therapeutic effect is
not entirely understood, it is thought that BH4 reduces phe serum levels
in some individuals with PKU by improving the folding conformation of
certain types ofmutant PAHmolecules resulting in increased phe catab-
olism (Erlandsen and Stevens, 2001; Erlandsen et al., 2004).
Not all individuals with PKU experience a decrease in blood phe
levels in response to BH4 treatment, and there is considerable variability
among those who do show a response (Burton et al., 2007). Multiple
factors appear to contribute to responsiveness as evidenced by the fact
that even individuals with identical PAH genotype may vary in BH4 re-
sponsiveness (Pérez et al., 2005). Within this context, in order to deter-
mine whether a given PKU patient is BH4 responsive, a trial period of
BH4 treatment is undertaken. Several different protocols for this trial
period have been developed, and metabolic clinics tend to use their
own guidelines for determining responsiveness (Bélanger-Quintana
et al., 2011). Typically, these protocols require that blood phe levels
decrease substantially (e.g., ≥20%) from baseline during a trial period
(e.g., 30 days) for a patient to be considered BH4-responsive.
1.2. The present study
As noted earlier, previous studies have found that improved
adherence to dietary phe restrictions (and resulting decreases in
serum phe levels) are associated with improvements in cognitive
performance and white matter structural integrity in patients with
PKU. Much less is known regarding BH4 treatment and its potential
impact on brain and cognition in PKU. To date, there are no pub-
lished studies on BH4 treatment in PKU and its effects on the func-
tional brain integrity, and few existing studies on BH4 treatment
and cognitive performance (e.g., Gassió et al., 2010; Lambruschini
et al., 2005).
The present study represents the ﬁrst examination of potential
changes in brain activation in patients with PKU during BH4 treatment.
To this end, we utilized an n-back workingmemory task in conjunction
with fMRI to evaluate functional brain integrity in a sample of individ-
uals with PKU at three timepoints: Just prior to BH4 treatment, after
4 weeks of treatment, and after 6 months of treatment. Neural activa-
tion patterns observed for the PKU treatment group were compared
with those of a demographically-matched sample of healthy non-PKU
individuals whowere assessed at identical time intervals. We hypothe-
sized that BH4 treatment in the PKUgroupwould be associatedwith im-
provements in workingmemory and related neural activity (i.e., neuralactivity in the PKUgroupwould closer approximate that observed in the
non-PKU group).
2. Material and methods
2.1. Study design
A sample of 12 patients with PKU received baseline fMRI evalua-
tions before beginning treatment with BH4. Phe response to BH4 was
monitored for 4 weeks. At the end of the 4 weeks, fMRI evaluations
were repeated. At this time, phe response to BH4 was also reviewed
by the patient's treating physician and a decision was made whether
to continue or discontinue treatment. [Note that this decision was
made independent of the current authors/research team.] The fMRI
evaluations were repeated again at the 6 month mark on those indi-
viduals who continued treatment. For comparison purposes, a demo-
graphically matched sample of 12 healthy individuals without PKU
also received fMRI evaluations at baseline, 4-week, and 6-month
timepoints. The non-PKU comparison group did not receive BH4
treatment.
2.2. Participants
A sample of 12 individuals (6 female, 6 male) with PKU ranging
in age from 9 to 33 years (M = 23.6; SD = 8.8) participated in the
study. Inclusionary criteria for participants were: (1) diagnosis at
birth with a blood phe level ≥ 360 μmol/L, (2) recent history of
phe levels ≥ 360 μmol/L, (3) ≥ 6 years of age, and (4) intention of
their treating physician to prescribe BH4. The PKU participant
group represented a sample of convenience and included individuals
referred from clinics at University of Missouri (n = 4), University of
Florida (n = 3), Kansas City Children's Mercy Hospital (n = 2),
Washington University in St. Louis (n = 1), University of Nebraska
(n = 1), and University of Kansas Medical Center (n = 1).
For all individuals with PKU, diagnosis was made and phe-
restricted dietary treatment was implemented shortly after birth,
as indicated bymedical records and/or patient report. Unfortunately,
complete lifetime records of blood phe level could not be attained for
several older participants in the sample. Recent blood phe levels,
however, were available for all participants. Although all patients
reported that they had continued to maintain phe-restricted dietary
treatment, a wide range of blood phe levels was observed in the PKU
group. Mean phe levels in the year prior study enrollment ranged
from 161 to 1459 μmol/L (group M = 827; SD = 356). Mean phe
levels for the month prior to study enrollment were similar (133 to
1459;M = 827, SD = 399).
An age- and gender-matched comparison sample of 12 neurological-
ly uncompromised individuals (7 female, 5 male)without PKUwas also
recruited. Participants in the non-PKU comparison group ranged in age
from 9 to 33 years (M = 24.2; SD = 8.9) and were recruited from the
Columbia, Missouri community.
The Wechsler Abbreviated Scale of Intelligence (Psychological
Corporation, 1999) was administered to estimate general intellec-
tual ability. For individuals in the PKU group, scores ranged from 73
to 115 (M = 99.7; SD = 11.0). For individuals in the non-PKU
group, scores ranged from102 to 120 (M = 111.0; SD = 7.0). As antic-
ipated based on previous studies (for review, see Brumm and Grant,
2010), we found that scores of the non-PKU group were signiﬁcantly
higher than those of the PKU group, t(22) = 3.02, p b .01.
Consistent with past studies, pre-treatment phe levels for the PKU
participants were positively correlated with age [prior month: r = .56,
p = .06; prior year: r = .59, p = .05] and negatively correlated with
IQ (phe level for prior year: r = −.78, p = .003; Phe level for prior
month: r = −.76, p = .004]. Age and IQ, however, were not correlated
with each other [r = −.27, p = .39]. Gender was also not related to
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all instances].
2.3. N-back working memory task
The n-backworkingmemory task represents one of themost widely
used paradigms within the cognitive neuroscience ﬁeld for study-
ing working memory (Smith and Jonides, 1999). The task is well-
established and has been used extensively to assess working memory
in both healthy (Owen et al., 2005) and clinical populations (Glahn
et al., 2005), including individuals with PKU (Christ et al., 2010b).
The n-back working memory task included two conditions: 2-back
and 0-back. In the 2-back condition, participants were shown a series
of letters one at a time (500 ms presentation time followed by a
1500 ms interstimulus blank period) and were instructed to respond
when the current letter was the same as the letter that appeared two
items prior. Letter stimuli were randomly drawn from the following
stimulus set: B, C, D, F, G, H, J, K, L, M, N, P, Q, R, S, T, V, W, Z. For the
0-back condition, participants were again shown a series of letters;
however, in this instance, they were asked to simply respond when
they saw the letter X (regardless of what preceded it).
Each functional run included 8 task epochs (4 per condition).
Immediately prior to each task epoch, a visual cue (i.e., the text
“***2-back***” or “***X-back***”) indicated the forthcoming task
condition; this cue was presented in red in themiddle of the visual dis-
play for 2000 ms followed by a 2000 ms blank interval. Each task epoch
lasted 32 s (not including the aforementioned cue) and comprised 4
target and 12 non-target stimuli randomly intermixed. The order of
condition administration (2-back vs. 0-back) within each functional
run was counterbalanced using an ABBA-BAAB design. Rest epochs
(20 s each), in which only a ﬁxation point was shown, were presented
at the beginning and end of each functional run and between the task
epochs. Each participant completed two functional runs of the task.
2.4. Data acquisition
Prior to entering the MRI scanner, each participant completed a
practice block of the working memory task designed to familiarize the
participant with the task as well as to control for any potential practice
effects that could otherwise contribute to performance.
Scans were obtained on a 3 T Siemens Trio scanner with a standard
8-channel head coil. Stimuli in the working memory task were
displayed using an LCD projector, and responses were recorded
using a ﬁber optic switch. For alignment purposes, a set of structural
imageswas collectedﬁrst using a standard T1-weighted pulse sequence
[MP-RAGE sequence: TR = 2400 ms, TE = 3.16 ms, ﬂip angle = 8°,
in-plane resolution = 1 × 1 mm, slice thickness = 1 mm, number of
slices = 176]. For each functional run, sets of 32 contiguous axial
images (TR = 2200 ms, TE = 27, ﬂip angle = 90°, in-plane resolu-
tion = 4.0 × 4.0 mm, slice thickness = 4.0 mm) were acquired paral-
lel to the anterior–posterior commissure plane. This procedure offered
whole-brain coverage at a high signal-to-noise ratio. As indicated
earlier, each participant completed a two functional runs.
2.5. Procedure
The present study was approved by the University of Missouri-
Columbia Internal ReviewBoard Study, registeredwith ClinicalTrials.gov
(NCT00964236), and completed in accordance with the Helsinki
Declaration. Informed consent was obtained for all participants,
and assent was obtained for all participants under 18 years of age
in addition to obtaining a parental consent.
2.5.1. Baseline assessment
All participants received a baseline fMRI evaluation. Shortly
thereafter (M = 1.9 days, SD = 4.6), participants with PKU beganBH4 treatment per standard clinical dosage amounts (20 mg/kg/day)
under the supervision of their treating physician. PKU participants
were instructed not to alter their usual dietary (protein) intake or
initiate/terminate any other treatments during the 4-week BH4
treatment trial period. Participants in the non-PKU comparison
group did not receive BH4 treatment.
2.5.2. Four-week assessment
Following fourweeks of BH4 treatment (M = 32.9 days, SD = 11.2),
participants with PKU received a follow-up fMRI evaluation. Also at this
time, patient blood phe responsiveness to treatment was evaluated.
Response to BH4 treatment was generally considered positive if a
reduction of ≥20% in blood phe occurred during the 4-week trial
period. Note, however, that the determination of response was made
separately by each participant's treating physician and without input
from the current authors/research team. As such, the treating physician
had latitude to consider other factors beyond phe levels (e.g., anecdotal
reports of improved behavior) when determining whether or not
to continue BH4 treatment. Following an equivalent time interval
(M = 33.3 days, SD = 10.6), participants in the non-PKU compari-
son group also received a follow-up fMRI evaluation.
2.5.3. Six-month assessment
Evaluations were repeated again following 6 months of treat-
ment (M = 202.7 days, SD = 45.7) for those individuals who were
continued on BH4 treatment. [Individuals with PKU who had been
discontinued on BH4 treatment by their treating physician at the
4-week mark did not complete this evaluation.] Following an equivalent
time interval (M = 217.1 days, SD = 43.2), participants in the non-
PKU comparison group also received a follow-up fMRI evaluation.
2.6. Data processing and statistical methods
Functional imaging data were preprocessed and analyzed using
BrainVoyager QX software (version 1.10; Brain Innovation, Maastricht,
the Netherlands). Preprocessing steps included slice scan time
correction, 3D motion correction, transformation to standardized
atlas space (Talairach and Tournoux, 1988), and spatial smoothing
(6 mm FWHM) to accommodate variations in activation loci across
participants. Functional runs with excessive motion (N3 mm) were
omitted from further analysis.
Statistical analysis was conducted using a random effects general
linear model approach. For each participant, the two task conditions
(2-back and 0-back) were modeled separately using a convolved box-
car response function. Confound predictors were also included in the
model to account for inter-volumemovement (3 predictors for transla-
tional movement and 3 predictors for rotational movement), linear
trend, and low frequency noise. For all voxel-wise comparisons, statisti-
cal and cluster thresholds of p b .05 and contiguous area of N500 mm3,
respectively, were used.
For the non-PKU group, beta values for the contrast of interest [2-
back N 0-back] were estimated separately for each participant. A series
of voxel-wise comparisons were conducted and conﬁrmed no signiﬁ-
cant changes in the activation pattern observed between the baseline,
4-week, and 6-month assessments for the non-PKU group. Based
on this ﬁnding, data for the non-PKU group were collapsed across
timepoint for later between-group comparisons. For the PKU group,
beta values were estimated separately for each participant and
timepoint (baseline, 4-week, and 6-month). We anticipated changes
related to BH4 treatment in the PKU group, hence timepoints contin-
ued to be modeled separately for this group.
3. Results
The participant ﬂow diagram is shown in Fig. 1. In short, four-week
assessments were completed by 11 of 12 participants with PKU that
Fig. 1. Participant ﬂowdiagram. Demographic information [mean age, gender, mean IQ, mean phe level for the year prior study enrollment, andmean blood phe level change (%) between
the baseline and 4-week evaluations] are included for each sub-group.
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continued on BH4 treatment beyond the 4-week timepoint, 5 com-
pleted the 6-month assessment. Of the initial 12 non-PKU partici-
pants, all 12 completed the 4-week assessment and 8 completed
the 6-month assessment.
As noted earlier, consistent with past research (Brumm and Grant,
2010), we found a signiﬁcant difference in IQ between the PKU and
non-PKU groups. Both statistical and conceptual concerns, however,
precluded us from including IQ as a covariate in our analyses. Given
the strong association between IQ and group membership, inclusion of
IQ as a covariate would lead to underestimation of the variance in the
dependent variable (working memory performance, neural activity)
attributable to the independent variable (groupmembership) thus ren-
dering the analysis results largely uninterpretable (for more extensive
treatment of this topic, see Miller and Chapman, 2001). Furthermore,
another critical assumption of ANCOVA is that the dependent variable
could not have caused group differences in the covariate (Overall and
Woodward, 1977; Wildt and Ahtola, 1978). Particularly as it relates
to the fMRI data, an argument can be made that PKU causes neu-
ral disruption (i.e., atypical neural activation – the dependent
variable) that, in turn, underlies the observed group differences
in IQ (the potential covariate).3.1. Working memory performance
Due to technical problems, n-back data were not available for two
non-PKU participants at the 4-week timepoint. So as to conceptually
parallel the previously described fMRI analysis approach, which focuses
on the contrast between the 2-back and 0-back conditions, the primary
dependent variable for the behavioral data analysis was the difference
in error rate between the 2-back and 0-back conditions. When the
analyses described below were repeated with the response time
data, no signiﬁcant effects of group, timepoint, or related interactions
were found (p N .05 in all instances). Also note that, due to the small
sample sizes involved, non-parametric statistical tests were used
for all comparisons among PKU subgroups (e.g., responders vs.
non-responders).3.1.1. Baseline assessment
The PKU group demonstrated signiﬁcantly poorer working memory
performance than the non-PKU group as reﬂected by the difference
score of error rate (%) in the 2-back condition minus that in the
0-back condition (MPKU = 8.8%; MNonPKU = 3.6%) [t(22) = 2.66,
p = .01]. Within the PKU group, no signiﬁcant relationship was
found between working memory performance and age [r = −.25,
p = .43], IQ scores [r = −.06, p = .86], or recent blood phe levels
[prior month: r = −.38, p = .222; prior year: r = −.33, p = .30].
3.1.2. Four-week assessment
Potential changes in working memory performance (as reﬂected by
the difference score of error rate in the 2-back condition minus that
in the 0-back condition) were evaluated using a mixed model ANOVA
with group (PKU and non-PKU) as the between-subjects factor, and
timepoint (baseline and 4-week) as the within-subjects factors. The
main effect of group approached signiﬁcance [F(1,19) = 3.52, p = .08].
However, neither a main effect of timepoint nor group × timepoint
interaction were found [F(1,19) b 1.8, p N .20 in both instances].
With the PKU group, the correlation between age and themagnitude
of change in working memory performance over the 4-week period
approached signiﬁcance [r = −.57, p = .07], with younger patients
showing greater change compared to older patients. No relationship
was seen between changes in workingmemory performance and base-
line IQ scores [r = .08, p = .81], or pre-treatment blood phe levels
[prior month: r = −.20, p = .56; prior year: r = −.16, p = .65].
For each PKU participant, his/her blood phe change was calculated
based on the mean phe level for the month prior to treatment and
the ﬁnal blood phe level recorded during the 4-week trial period
[% Phe Change = 100 * (PheWeek4 – PhePreTx)/PhePreTx]. Blood phe
changes for the PKU group ranged widely (−91% to +36%) with a
mean response of−34.8% (SD = 35.7). Of particular interest, no re-
lationship was seen between the magnitude of phe level change and
an individual's change in working memory performance during the
same time period (4-week performance minus baseline performance)
[r = .06, p = .85]. The magnitude of phe level change was also not
correlated with age [r = −.25, p = .46], baseline IQ scores [r = −.47,
p = .15], baseline working memory performance [r = −.02, p = .96],
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year: r = .36, p = .28].
Given that there was not perfect correspondence between the
magnitude of phe level change and the designation of participants
as ‘responders’ or ‘non-responders’ (treating physicians had the
latitude to consider additional factors), additional analyses were
conducted comparing these two subgroups. As anticipated, the Re-
sponder subgroup (M = −50.9%, SD = 28.9) showed a larger drop
in blood phe levels as compared to the PKU Non-Responder sub-
group (M = −6.4%, SD = 30.0). The two subgroups did not differ
signiﬁcantly in age, IQ scores, or pre-treatment blood phe levels
[Mann–Whitney U ≥ 5.0, p N .10 in all instances]. They also did not
differ from each other in terms of working memory performance at
baseline or the 4-week timepoint, or themagnitude of change in per-
formance between these two timepoints [Mann–Whitney U ≥ 12,
p N .78 in all instances].
3.1.3. Six-month assessment
As detailed previously, only those PKU participants who continued
on BH4 treatment (as per their treating physician) completed the
6-month follow-up assessment. Data for this PKU ‘Responder’ subgroup
and the non-PKU group were entered into a mixed model ANOVA with
group and timepoint as factors. No main effect of group was found
[F(1,11) = 2.84, p = .12]. The main effect of timepoint was signiﬁcant
[F(1,11) = 7.82, p = .02]. Most importantly, there was also a signif-
icant interaction between group and timepoint [F(1,11) = 7.13,
p = .03]. As can be seen in Fig. 2, subsequent analysis conﬁrmed
that this effect was driven by an improvement between baseline
and the 6-month assessment in PKU Responder subgroup's perfor-
mance (MBaseline = 9.1%; M6Month = 5.0%) [Wilcoxon signed-ranks
Z = −2.02, p = .04]. No relationship was seen between changes in
working memory performance at the 6-month timepoint and age
[rs = .00, p = 1.00], baseline IQ scores [rs = .10, p = .87], or pre-
treatment blood phe levels [prior month: rs = −.10, p = .87; prior
year: rs = −.10, p = .87].
For each PKU participant, his/her blood phe change during the
6 months was calculated based on the mean phe level for the month
prior to treatment and the mean blood phe level for the subsequent
6 months. Blood phe changes for the PKU group ranged from −57%Fig. 2.Working memory performance (as reﬂected as reﬂected by the difference score of
error rate in the 2-back condition minus that in the 0-back condition) shown separately
for timepoint (baseline, week 4, and 6 month) and BH4 responsiveness as determined
independently at the 4-week timepoint by each participant's treating physician.
[Patients deemed “non-responders” were discontinued on BH4 treatment after the
4-week trial period. “Responders” were continued on BH4 treatment and remained
in the present study through the 6-month timepoint.] For comparison purposes, the
mean and standard error of the behavioral performance observed for the non-PKU
group are represented by a dashed line and gray shaded area, respectively.to +51% with a mean difference of−14.6% (SD = 44.4). The corre-
lation between the magnitude of phe level change and an
individual's change in task performance during the same time period
(6-month performance minus baseline performance) approached
signiﬁcance [rs = −.80, p = .10], with greater drop in phe levels as-
sociated with larger improvement in working memory performance.
No relationship was evident between the magnitude of phe level
change and age [rs = −.10, p = .87], baseline IQ scores [rs = .40,
p = .51], or pre-treatment blood phe levels [prior month: rs = −.10,
p = .87; prior year: rs = −.10, p = .87].
3.2. fMRI results
Due to excessive head motion, neuroimaging data were unusable
for 2 non-PKU participants at the 4-week timepoint and 1 non-PKU
participant at the 6-month timepoint.
3.2.1. Baseline assessment
As illustrated in Fig. 3, signiﬁcant group-related differences in activa-
tion were observed for several regions-of-interest (ROIs). The location,
size, and statistical values associated with each of these ROIs (n = 15)
are further detailed in Table 1.
Within the PKUgroup, ROIs in right inferior parietal lobule (region 0),
right middle frontal gyrus (region 6), and left middle frontal gyrus
(region 12) showed signiﬁcant correlations between the magnitude
of activation and recent blood phe levels [r N .61, p b .05 in all
instances]. No relationships were seen between ROI activation and age
or IQ with a two exceptions: The aforementioned ROI in right inferior
parietal lobule (region 0) also showed a marginal correlation between
activation and age [r = .49, p = .10]. An ROI in bilateral precuneus
(region 2) showed a marginal correlation between activation and IQ
[r = −.53, p = .08].
3.2.2. Four-week assessment
The aforementioned ROIs identiﬁed at baseline as showing signiﬁ-
cant group-related differences in activations were assessed for possible
changes in activation between baseline and 4-week evaluation in the
PKU group. As illustrated in the top two panels of Fig. 4, one-tailed
paired samples t tests revealed signiﬁcant changes in activation be-
tween the baseline and 4-week evaluations for regions in left inferior
parietal lobule (region 8) [t(10) = 2.27, p = .02] and bilateral anterior
cingulate cortex (region 13) [t(10) = 2.05, p = .03]. In both cases, the
activation pattern observed at the 4-week evaluation better approxi-
mated that observed for the non-PKU group.
Interestingly, the magnitude of activation change between the
baseline and 4-week evaluations in the aforementioned inferior
parietal lobule ROI (region 8) was marginally correlated with con-
current changes in blood phe levels [r = −.58, p = .07]. Greater
drop in phe levels was associated with less activation (which better
approximated the non-PKU group). A similar relationship was not ob-
served for the bilateral anterior cingulate ROI (region 13) [r = .13,
p = .70]. Changes in activation of the two ROIs were not related to
age [|r| b .28, p N .41], baseline IQ scores [|r| b .15, p N .66], or pre-
treatment blood phe levels [prior month: |r| b .47, p N .14; prior year:
|r| b .50, p N .11].
In comparing the responder and non-responder PKU subgroups,
the two groups did not differ in baseline activation for either ROI
[Mann–Whitney U ≥ 5.0, p N .10 in both instances]. The magnitude
of activation change observed between baseline and the 4-week
timepoint for the two ROIs was also similar for the subgroups
[Mann–Whitney U ≥ 10, p N .52 in both instances].
3.2.3. Six-month assessment
For the PKU responder subgroup (i.e., participants who remained on
BH4 treatment), the baseline ROIs were assessed for possible activation
changes between baseline and 6-month evaluation. As shown in the
Fig. 3. The left and center panels illustrate signiﬁcant task-related (2-back minus 0-back) activity, shown separately for the non-PKU group and PKU group, respectively. The right panel
illustrates regions demonstrating signiﬁcant group differences in task-related activity. Results are viewed on the inﬂated surface of an exemplar brain. Statisticalmapswere thresholded at
p b .005 and p b .05, respectively, for illustration purposes.
544 S.E. Christ et al. / NeuroImage: Clinical 3 (2013) 539–547bottom panel of Fig. 4, a signiﬁcant change was observed for a region in
rightmiddle temporal gyrus (region 3) [t(4) = 2.60, p = .03].Working
memory-related activation better approximated that of the non-PKUTable 1
Regions exhibiting a group (non-PKU and PKU) differences in task-related (2-back minus 0-ba
Peak activation
Region Location BA x y z
PKU N non-PKU
0 Right inferior parietal lobule 40 39 −61 32
1 Right fusiform gyrus 19 24 −74 −7
2 Bilateral precuneus 7, 31 −1 −71 28
3 Right middle temporal gyrus 21 40 2 −22
4 Right inferior parietal lobule 40 53 −36 25
5 Right hippocampus NA 24 −18 −9
6 Right middle frontal gyrus 8 37 9 30
7 Bilateral superior frontal gyrus 9 5 57 26
8 Left inferior parietal lobule 7, 19, 40 −42 −61 29
non-PKU N PKU
9 Left superior frontal gyrus 6 −23 −5 57
10 Left intraparietal sulcus 7, 40 −25 −52 35
11 Left middle temporal gryus 21 −45 0 −11
12 Left middle frontal gyrus 9, 46 −34 41 25
13 Bilateral anterior cingulate 32 2 2 46
14 Right precuneous 7 17 −50 44
Notes. NA: Not applicable. BA: approximate Brodmann's area.
⁎ Degrees of freedom = 22.comparison group (mean % signal change = −.10) at the 6-month
assessment (mean % signal change = −.14) than at baseline (mean %
signal change = .06). Themagnitude of the observed activation changeck) activity.
Volume Mean signal change (%) Effect size
(mm3) non-PKU PKU t value⁎ p value (d)
5421 0.01 0.28 3.61 .002 1.54
1665 −0.08 0.10 2.83 .010 1.21
3814 −0.11 0.18 3.58 .002 1.53
733 −0.09 0.04 3.27 .003 1.39
1888 0.02 0.24 3.04 .006 1.30
541 −0.13 0.05 2.64 .015 1.13
514 0.11 0.29 2.96 .007 1.26
616 −0.41 −0.13 3.04 .006 1.30
973 −0.11 0.17 2.80 .011 1.19
1194 0.39 0.12 2.82 .010 1.20
781 0.25 0.12 3.37 .003 1.44
893 0.06 −0.15 3.12 .005 1.33
1621 0.31 0.06 3.17 .004 1.35
877 0.25 0.05 2.49 .021 1.06
514 0.14 0.03 2.73 .012 1.16
Fig. 4. The pattern of activation for three ROIs that demonstrated signiﬁcant changes in activation over time with BH4 treatment. The upper and middle panels illustrate regions in left
inferior parietal lobule (region 08) and bilateral anterior cingulate cortex (region 13) that showed signiﬁcant changes between baseline and 4-week evaluation (p b .05 in all instances).
The bottom panel illustrates a region in right middle temporal gyrus (region 03) that showed signiﬁcant changes between baseline and 6-month evaluation. Data is graphed separately
for timepoint (baseline,week 4, and 6 month) andBH4 responsiveness (responder vs. non-responder) as determined independently at the 4-week timepoint by eachparticipant's treating
physician. For comparison purposes, the mean and standard error of the activation levels observed for the non-PKU group are represented by a dashed line and blue shaded
area, respectively.
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546 S.E. Christ et al. / NeuroImage: Clinical 3 (2013) 539–547was not signiﬁcantly correlated with age, IQ, pre-treatment blood phe
levels, or blood phe level change between baseline and the 6-month
timepoint [|rs| b .40, p N .23].
4. Discussion
As anticipated based on past behavioral studies (Christ et al.,
2010a), we found that the PKU group performed more poorly than
the non-PKU comparison group on the working memory task at base-
line (without BH4 treatment). In terms of neuroimaging ﬁndings, PKU
was associated with atypical activation of several regions in prefrontal
and parietal cortex (e.g., bilateral dorsolateral prefrontal cortex, anteri-
or cingulate cortex, left intraparietal sulcus) known to be critical for
working memory (Owen et al., 2005). The prefrontal cortex ﬁnding is
generally consistent with the hypothesis that PKU-related depletion in
dopamine leads to prefrontal dysfunction which, in turn, contributes
to the executive function impairments often seen in this population
(Diamond, 1996; Welsh, 1996).
Group-related differences in activation patterns were also observed
in areas (e.g., left inferior parietal lobule, right hippocampal area)
known to be part of the default mode network, a network of
interconnected brain regions that are generally more active when a
person is at rest compared with when he/she is performing a cogni-
tive task (for review, see van den Heuvel and Hulshoff Pol, 2010). In
the non-PKU group, as expected these regions showed signiﬁcant
deactivation in the 2-back condition as compared to the cognitively
less demanding 0-back condition. In the PKU group, however, these
regions showed little or no difference in activation between the
two conditions. This ﬁnding is consistent with our previous two
functional neuroimaging studies of PKU (Christ et al., 2010b, 2012),
both of which also found PKU-related disruptions in the default
mode network.
Curiously, superimposed on the aforementioned patterns of atypical
activation, there appeared to also be a trend towards under-activation of
left brain areas and over-activation of right brain areas in the PKU group
as compared to the non-PKU group. Although speculative, this pattern
could be related to impairment in the utilization of verbal-based
encoding and strategies (e.g., Banerjee et al., 2011) thus forcing the
PKU group to rely more heavily on less optimal, non-verbal strate-
gies supported primarily by the right hemisphere.
Following four weeks of BH4 treatment, changes in neural activation
but notworkingmemory performancewere observed in the PKUgroup.
Regions showing signiﬁcant changes included a ‘task positive’ working
memory-related region in anterior cingulate cortex and a ‘task negative’
defaultmodenetwork region in left inferior parietal lobule. Importantly,
after 4 weeks of treatment, the activation pattern for the PKU group
better approximated that observed for the non-PKU group in both
cases. In addition, as can be seen in Fig. 4, this pattern continued to
hold for these regions at the 6-month timepoint as well.
Following an additional ﬁve months of continued treatment, im-
provements in working memory performance were now evident.
Error rate in the 2-back condition for the PKU group dropped from
10.0% and 10.8% at baseline and the 4-week timepoints, respectively,
to 6.9% at the 6-month follow. During the same time period, perfor-
mance for the non-PKU group remained relatively stable (baseline =
5.7%, 4-week = 4.9%, 6-month = 4.8%). An additional change in neural
activity was also observed. A region in lateral right temporal cortex,
which represents another default mode network region, showed better
approximation to the non-PKU activation pattern with treatment.
As illustrated in Fig. 4, a trend was present at the 4-week timepoint
but the change did not reach signiﬁcance until the 6-month timepoint.
The primary mechanism-of-action for BH4 treatment in PKU is
believed to be the activation of residual PAH enzyme (Erlandsen and
Stevens, 2001). Consistent with this, we found tentative evidence of a
relationship between phe level changes during treatment andmeasure-
ments of neural activity andworkingmemory performance. Speciﬁcally,a larger drop in phe levels was associated a greater improvement in
neural activity at the 4-week timepoint andworkingmemory perfor-
mance at the 6-month timepoint. Consistent with the notion that
neuroplasticity varies with age (i.e., the “Kennard principle”), the
current analysis also revealed a potential relationship between age
and the changes in working memory performance observed for
PKU participants. Younger PKU participants (as compared to older
participants) showed greater gains in workingmemory performance
over the ﬁrst four weeks of treatment. Additional research with a
larger sample size is critical in conﬁrming these ﬁndings.
4.1. Limitations and future directions
Thepresent sample size is reﬂective of the rarity of PKU (1 in 15,000)
as well as the general challenge of conducting treatment-related longi-
tudinal research. The sample size provided sufﬁcient statistical power to
detect the aforementioned changes in task performance and brain activ-
ity. Future research employing larger sample sizes, however,may reveal
additional (more subtle) changes in neural activity and task perfor-
mance that otherwise went undetected in the current study.
A larger sample size would also allow for a proper evaluation of
the extent to which factors such as age and prior treatment history
(e.g., historic phe levels) may moderate treatment-related changes
in cognitive and neural function. Longer-term study is also needed.
Additional behavioral and/or neural changes might be apparent if
one were to follow patients receiving BH4 treatment beyond the
time period (6 months) included in the present study. For example,
changes in not only brain activation but also structure (e.g., the severity
of white matter abnormalities) might occur.
Another potential limitation relates to the fact that only those PKU
participants whowere deemed ‘responders’ by their treating physicians
were continued on BH4 treatment beyond the 4-week trial period
and completed the 6-month evaluation. Although the ‘responding’
and ‘non-responding’ groups in the present study appeared demo-
graphically indistinguishable from one another (see Fig. 1), the se-
lect nature of this group necessitates that the 6-month ﬁndings be
interpreted with caution. Future studies in which all participants,
regardless of initial blood phe response, are continued on BH4 treat-
ment and complete long term follow-up is needed.
Such research would allow us to explore the possibility that BH4
may have therapeutic beneﬁts in PKU beyond its effect on phe me-
tabolism. BH4 serves as a cofactor for several other metabolic pro-
cesses including the conversions of tyrosine to L-DOPA, tryptophan
to 5-hydroxtryptophan, L-arginine to nitric oxide, and 1-alkyl-sn-
glycerol to 1-hydroxyalkyl-sn-glycerol (Fitzpatrick, 1999; Kappock
and Caradonna, 1996; Marletta, 1993). Although speculative, it re-
mains possible that BH4 treatment-related changes in these addi-
tional processes may have contributed to the neurocognitive changes
observed in the current study. Indeed, reports of positive outcome fol-
lowing BH4 treatment in non-PKU clinical populations such as autism
and depression conﬁrm these pathways as viable therapeutic targets
and sites of action for BH4 treatment (e.g., Bottiglieri et al., 1992;
Danfors et al., 2005; Nakamura et al., 2006).
4.2. Summary and conclusions
The current study represents the ﬁrst examination of changes in
neural activation in patients with PKU during BH4 treatment. Consistent
with past research, baseline evaluation revealed impaired executive
function and atypical brain activation patterns in the PKUgroup as com-
pared to the non-PKU group. Most importantly, BH4 treatment was
associated with improvements in both behavioral performance and
brain activation, with the latter evident earlier (4-week timepoint) as
compared to the behavioral aspect (6-month timepoint). Future re-
search with larger sample sizes is needed to disentangle the extent to
547S.E. Christ et al. / NeuroImage: Clinical 3 (2013) 539–547which the observed improvements were due to improved metabolism
of phe versus potential secondary therapeutic pathways of BH4.Acknowledgements
This research was funded by a research grant from BioMarin
Pharmaceutical Inc. The authors conﬁrm independence from the
sponsors; the content of the article has not been inﬂuenced by the
sponsors. The authors would also like to thank the participants and
their families for their time and participation, which contributes to
knowledge to better understand PKU. We would like to thank the
faculty and staff of the metabolic clinics at the University of Missouri,
University of Florida, Kansas City Children'sMercyHospital,Washington
University in St. Louis, University of Nebraska, and University of Kansas
Medical Center for their assistance with participant recruitment and
data collection.References
Anderson, P.J., Leuzzi, V., 2010. White matter pathology in phenylketonuria. Mol. Genet.
Metab. 99 (Suppl. 1), S3–S9.
Antenor-Dorsey, J.A.V., Hershey, T., Rutlin, J., Shimony, J.S., McKinstry, R.C., Grange, D.K.,
White, D.A., 2013. White matter integrity and executive abilities in individuals with
phenylketonuria. Mol. Genet. Metab. 109, 125–131.
Banerjee, P., Grange, D.K., Steiner, R.D., White, D.A., 2011. Executive strategic process-
ing during verbal ﬂuency performance in children with phenylketonuria. Child
Neuropsychol. 17, 105–117.
Bélanger-Quintana, A., Burlina, A., Harding, C.O., Muntau, A.C., 2011. Up to date knowl-
edge on different treatment strategies for phenylketonuria. Mol. Genet. Metab. 104,
S19–S25 (Suppl.).
Bottiglieri, T., Hyland, K., Laundy,M., Godfrey, P., Carney, M.W., Toone, B.K., Reynolds, E.H.,
1992. Folate deﬁciency, biopterin andmonoaminemetabolism in depression. Psychol.
Med. 22, 871–876.
Brumm, V.L., Grant, M.L., 2010. The role of intelligence in phenylketonuria: a review of
research and management. Mol. Genet. Metab. 99 (Suppl. 1), S18–S21.
Burton, B.K., Grange, D.K., Milanowski, A., Vockley, G., Feillet, F., Crombez, E.A.,
Dorenbaum, A., 2007. The response of patients with phenylketonuria and ele-
vated serum phenylalanine to treatment with oral sapropterin dihydrochloride
(6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study.
J. Inherit. Metab. Dis. 30, 700–707.
Christ, S.E., Huijbregts, S.C.J., de Sonneville, L.M.J.,White, D.A., 2010a. Executive function in
early-treated phenylketonuria: proﬁle and underlying mechanisms. Mol. Genet.
Metab. 99 (Suppl. 1), S22–S32.
Christ, S.E., Mofﬁtt, A.J., Peck, D., 2010b. Disruption of prefrontal function and connectivity
in individuals with phenylketonuria. Mol. Genet. Metab. 99 (Suppl. 1), S33–S40.
Christ, S.E., Mofﬁtt, A.J., Peck, D., White, D.A., Hilgard, J., 2012. Decreased functional brain
connectivity in individualswith early-treated phenylketonuria: evidence from resting
state fMRI. J. Inherit. Metab. Dis. 35, 807–816.
Cleary, M.A., Walter, J., Wraith, J., Jenkins, J., Alani, S., Tyler, K., Whittle, D., 1994. Magnetic
resonance imaging of the brain in phenylketonuria. Lancet 344, 87–90.
Danfors, T., von Knorring, A.-L., Hartvig, P., Langstrom, B., Moulder, R., Stromberg, B.,
Eeg-Olofsson, O., 2005. Tetrahydrobiopterin in the treatment of children with
autistic disorder: a double-blind placebo-controlled crossover study. J. Clin.
Psychopharmacol. 25, 485–489.
Diamond, A., 1996. Evidence for the importance of dopamine for prefrontal cortex
functions early in life. Philos. Trans. R. Soc. B-Biol. Sci. 351, 1483–1494.
Erlandsen, H., Pey, A.L., Gámez, A., Pérez, B., Desviat, L.R., Aguado, C., Stevens, R.C., 2004.
Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria
patients with certain phenylalanine hydroxylase mutations. Proc. Natl. Acad. Sci. U. S.
A. 101, 16903–16908.Erlandsen, H., Stevens, R.C., 2001. A structural hypothesis for BH4 responsiveness in pa-
tients with mild forms of hyperphenylalaninaemia and phenylketonuria. J. Inherit.
Metab. Dis. 24, 213–230.
Fitzpatrick, P.F., 1999. Tetrahydropterin-dependent amino acid hydroxylases. Annu. Rev.
Biochem. 68, 355–381.
Gassió, R., Vilaseca, M.A., Lambruschini, N., Boix, C., Fusté, M.E., Campistol, J., 2010. Cogni-
tive functions in patients with phenylketonuria in long-term treatment with
tetrahydrobiopterin. Mol. Genet. Metab. 99 (Suppl. 1), S75–S78.
Glahn, D.C., Ragland, J.D., Abramoff, A., Barrett, J., Laird, A.R., Bearden, C.E., Velligan, D.I.,
2005. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimag-
ing studies of working memory in schizophrenia. Hum. Brain Mapp. 25, 60–69.
Güttler, F., Lou, H., 1986. Dietary problems of phenylketonuria: effect on CNS transmitters
and their possible role in behaviour and neuropsychological function. J. Inherit.
Metab. Dis. 9 (Suppl. 2), 169–177.
Hegge, K.A., Horning, K.K., Peitz, G.J., Hegge, K., 2009. Sapropterin: a new therapeutic
agent for phenylketonuria. Ann. Pharmacother. 43, 1466–1473.
Hughes, J.V., Johnson, T.C., 1978. Experimentally induced and natural recovery from the
effects of phenylalanine on brain protein synthesis. Biochim. Biophys. Acta 517,
473–485.
Jervis, G.A., 1953. Phenylpyruvic oligophrenia deﬁciency of phenylalanine-oxidizing sys-
tem. Proc. Soc. Exp. Biol. Med. 82, 514–515.
Kappock, T.J., Caradonna, J.P., 1996. Pterin-dependent amino acid hydroxylases. Chem.
Rev. 96, 2659–2756.
Koch, R., Burton, B., Hoganson, G., Peterson, R., Rhead, W., Rouse, B., Azen, C., 2002. Phe-
nylketonuria in adulthood: a collaborative study. J. Inherit. Metab. Dis. 25, 333–346.
Kure, S., Hou, D.C., Ohura, T., Iwamoto, H., Suzuki, S., Sugiyama, N., Narisawa, K., 1999.
Tetrahydrobiopterin-responsive phenylalanine hydroxylase deﬁciency. J. Pediatr.
135, 375–378.
Lambruschini, N., Pérez-Dueñas, B., Vilaseca, M.A., Mas, A., Artuch, R., Gassió, R.,
Campistol, J., 2005. Clinical and nutritional evaluation of phenylketonuric patients
on tetrahydrobiopterin monotherapy. Mol. Genet. Metab. 86 (Suppl. 1), S54–60.
Marletta, M.A., 1993. Nitric oxide synthase structure and mechanism. J. Biol. Chem. 268,
12231–12234.
Miller, G.A., Chapman, J.P., 2001. Misunderstanding analysis of covariance. J. Abnorm.
Psychol. 110, 40–48.
Nakamura, K., Sugawara, Y., Sawabe, K., Ohashi, A., Tsurui, H., Xiu, Y., Hirose, S., 2006. Late
developmental stage-speciﬁc role of tryptophan hydroxylase 1 in brain serotonin
levels. J. Neurosci. 26, 530–534.
Overall, J.E.,Woodward, J.A., 1977. Nonrandom assignment and the analysis of covariance.
Psych. Bull. 84, 588–594.
Owen, A., McMillan, K., Laird, A., Bullmore, E., 2005. N-back working memory paradigm: a
meta-analysis of normative functional neuroimaging studies. Hum. Brain Mapp. 25,
46–59.
Pérez, B., Desviat, L.R., Gómez-Puertas, P., Martínez, A., Stevens, R.C., Ugarte, M., 2005.
Kinetic and stability analysis of PKUmutations identiﬁed in BH4-responsive patients.
Mol. Genet. Metab. 86 (Suppl. 1), S11–S16.
Psychological Corporation, 1999. Wechsler Abbreviated Scale of Intelligence. Psycho-
logical Corporation, San Antonio, TX.
Ribas, G.S., Sitta, A., Wajner, M., Vargas, C.R., 2011. Oxidative stress in phenylketonuria:
what is the evidence? Cell. Mol. Neurobiol. 31, 653–662.
Smith, E.E., Jonides, J., 1999. Storage and executive processes in the frontal lobes. Science
283, 1657–1661.
Talairach, J., Tournoux, P., 1988. Co-planar sterotaxic atlas of the human brain. Thieme,
New York.
Thompson, A.J., Tillotson, S., Smith, I., Kendall, B., Moore, S., Brenton, D., 1993. Brain MRI
changes in phenylketonuria. Associations with dietary status. Brain 116, 811–821.
Van den Heuvel, M.P., Hulshoff Pol, H.E., 2010. Exploring the brain network: a review
on resting-state fMRI functional connectivity. Eur. Neuropsychopharmacol. 20,
519–534.
Waisbren, S.E., Noel, K., Fahrbach, K., Cella, C., Frame, D., Dorenbaum, A., Levy, H., 2007.
Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic
literature review and meta-analysis. Mol. Genet. Metab. 92, 63–70.
Welsh, M., 1996. A prefrontal dysfunction model of early-treated phenylketonuria.
Eur. J. Pediatr. 155, S87–S89.
Welsh, M., Pennington, B.F., Ozonoff, S., Rouse, B., McCabe, E., 1990. Neuropsychology of
early-treated phenylketonuria: speciﬁc executive function deﬁcits. Child Dev. 61,
1697–1713.
Wildt, A.R., Ahtola, O.T., 1978. Analysis of covariance. Sage, Beverly Hills.
